Caribou Biosciences Inc

NASDAQ CRBU

Data sourced from iex and EODHD
Download Data

Caribou Biosciences Inc Return on Equity (ROE) 5 year CAGR for the Trailing 12 Months (TTM) ending March 31, 2024

Caribou Biosciences Inc Return on Equity (ROE) 5 year CAGR is NA for the Trailing 12 Months (TTM) ending March 31, 2024. Return on equity (ROE) measures the profitability of a company relative to its shareholders' equity. It is calculated by dividing the net income by the shareholders' equity. This ratio indicates the return generated for each unit of shareholders' equity invested in the company. A higher ROE suggests better profitability and value creation for shareholders. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Caribou Biosciences Inc Return on Equity (ROE) for the Trailing 12 Months (TTM) ending March 31, 2023 was -8.35%, a -316.80% change year over year.
  • Caribou Biosciences Inc Return on Equity (ROE) for the Trailing 12 Months (TTM) ending March 31, 2022 was 3.85%, a -92.27% change year over year.
  • Caribou Biosciences Inc Return on Equity (ROE) for the Trailing 12 Months (TTM) ending March 31, 2021 was 49.80%.
NASDAQ: CRBU

Caribou Biosciences Inc

CEO Dr. Rachel E. Haurwitz Ph.D.
IPO Date July 23, 2021
Location United States
Headquarters 2929 7th Street, Berkeley, CA, United States, 94710
Employees 158
Sector Healthcare
Industry Biotechnology
Description

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

StockViz Staff

September 20, 2024

Any question? Send us an email